Yantai Heyuan AIDIS Biopharmaceutical Technology

Heyuan AIDIS is a clinical-stage biopharmaceutical company based in Yantai, China, specializing in the development of next-generation antibody-drug conjugates (ADCs) for oncology. The company utilizes a proprietary site-specific conjugation platform designed to improve the stability and therapeutic index of its drug candidates compared to traditional ADC technologies. Its lead program, MRG002, is a HER2-targeted ADC currently undergoing clinical evaluation for various solid tumors, including breast and gastric cancers. Heyuan AIDIS focuses on addressing unmet medical needs in the cancer space through precision medicine and innovative linker-payload combinations. The company's pipeline also includes candidates targeting TROP2 and other validated tumor antigens.